Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

620
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
620
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

531
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
531
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

679
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
679
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

3.4K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.4K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

170
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term citrate treatment in high-risk kidney stone formers is not associated with metabolic adverse effects.

Clinical kidney journal·2026
Same author

Ablatio-bilica: safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer undergoing systemic anti-tumor therapy: a phase II, multi-center, randomized, and controlled study.

Frontiers in oncology·2026
Same author

Identifying recurrent stone formers with machine learning: A single-centre observational study.

BJUI compass·2026
Same author

Transferrin-dependent uptake and distribution of iron in osteoclast-like cells.

Bone reports·2026
Same author

Deep biochemical phenotyping reveals prognostic value of rare genetic variants in adult kidney stone disease.

The Journal of clinical investigation·2026
Same author

Epidemiology and risk factors of urolithiasis: insights from SKIPOGH, a population-based cohort study in Switzerland.

Clinical kidney journal·2026

Related Experiment Video

Updated: Jun 28, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
07:45

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Published on: February 9, 2021

3.6K

Thiazides for kidney stone recurrence prevention.

Matteo Bargagli1, Sven Trelle2, Olivier Bonny3

  • 1Department of Nephrology and Hypertension, Inselspital, Bern University Hospital.

Current Opinion in Nephrology and Hypertension
|April 12, 2024
PubMed
Summary

Thiazide diuretics are commonly prescribed for kidney stone prevention but recent trials show limited efficacy and potential harms like diabetes and gout. Current evidence suggests thiazide monotherapy is not significantly better than placebo for preventing kidney stone recurrence.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K
A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 28, 2025

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis
07:45

Estimation of Urinary Nanocrystals in Humans using Calcium Fluorophore Labeling and Nanoparticle Tracking Analysis

Published on: February 9, 2021

3.6K
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.2K
A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.4K

Area of Science:

  • Nephrology
  • Pharmacology
  • Urology

Background:

  • Kidney stones are a common condition with high recurrence rates.
  • Thiazide diuretics are frequently used to prevent kidney stone recurrence.
  • Recent clinical trials have questioned the efficacy of thiazides for this purpose.

Purpose of the Study:

  • To assess the evidence for thiazides in preventing kidney stone recurrence.
  • To highlight potential adverse effects of thiazide treatment.
  • To identify areas for future research in kidney stone prevention.

Main Methods:

  • Review of current evidence on thiazide use for kidney stone prevention.
  • Analysis of findings from the NOSTONE trial.
  • Meta-analysis of randomized placebo-controlled trials with thiazide monotherapy.

Main Results:

  • The NOSTONE trial found hydrochlorothiazide not superior to placebo in preventing kidney stone recurrence.
  • Adverse events, including new-onset diabetes and gout, were more frequent with hydrochlorothiazide.
  • Current trial evidence does not support thiazide monotherapy being significantly better than placebo.

Conclusions:

  • Advocacy for restrictive use of thiazides due to limited efficacy and adverse effects.
  • There is a significant unmet need for effective kidney stone recurrence therapies.
  • Further research is needed to identify better prevention strategies.